Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings COGS-to-Revenue?

Freeline Therapeutics Holdings's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.01 Mil.

Freeline Therapeutics Holdings's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Freeline Therapeutics Holdings's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

Freeline Therapeutics Holdings COGS-to-Revenue Historical Data

The historical data trend for Freeline Therapeutics Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings COGS-to-Revenue Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial													-	-	-	-	-

Freeline Therapeutics Holdings COGS-to-Revenue Calculation

Freeline Therapeutics Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Freeline Therapeutics Holdings's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.005
	=	0.00

Freeline Therapeutics Holdings (NAS:FRLN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Freeline Therapeutics Holdings's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.005
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Freeline Therapeutics Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.